Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham breast team

European Journal of Surgical Oncology

Volumn 27, Issue 3, 2001, Pages 229-238

  Rampaul, R S ^a   Pinder, S E ^a   Elston, C W ^a   Ellis, I O ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Predictive factors; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; DROLOXIFENE; ESTROGEN RECEPTOR; FADROZOLE; FLUOROURACIL; GOSERELIN; GROWTH FACTOR RECEPTOR; MEGESTROL; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ASPIRATION BIOPSY; AWARENESS; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEALTH EDUCATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASS SCREENING; MASTECTOMY; MEDICAL DECISION MAKING; ONCOGENE NEU; PATIENT CARE; PATIENT COUNSELING; PATIENT RIGHT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL LINE; TUMOR DIFFERENTIATION; TUMOR VOLUME; UNITED KINGDOM; VASCULAR DISEASE;

EID: 0034937342     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2001.1114     Document Type: Article

References (123)

1. Breast cancer screening with mammography; overview of Swedish randomised trials
2. Effect of NHS Breast Screening Programme on mortality from breast cancer in England and Wales, 1990-1998: Comparison with observed and predicted mortality
3. Early experience in breast cancer screening: Emphasis on development of protocols for triple assessment
4. Integrating prognostic factors
5. The Nottingham Prognostic Index in primary breast cancer
6. Do we really need prognostic factors for breast cancer?
7. Time to abandon TNM staging of breast cancer?
8. Consensus document on staging for breast cancer
9. Relation of tumour size, lymph node status, and survival in 24,740 breast cancer cases
10. The Cancer Research Campaign (Kings/Cambridge) trial for early breast cancer - Pathological aspects
11. Staging of breast cancer and survival rates: An assessment based on 50 years of experience with radical mastectomy
12. Prognostic significance of number and level of axillary node metastases in breast cancer
13. Pathologic findings from the National Surgical Adjuvant Project for breast cancer (protocol) no 4). Discrimination for tenth year treatment failure
14. Observations and thoughts on carcinoma of the breast
15. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer
16. Axillary dissection in primary breast cancer; the benefits of node clearance warrant reappraisal
17. Clinical aspects of malignant disease
18. Staging the axilla in breast cancer: An audit of lymph-node retrieval in one UK regional centre
19. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: A controlled randomized trial
20. Axillary sampling in breast cancer: An assessment of its efficacy
21. Management of the axilla in operable breast cancer treated by breast conservation: A randomized clinical trial
22. An approach for the treatment of penile carcinoma
23. Technical details of intraoperative lymphatic mapping for early stage melanoma
24. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
25. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
26. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer
27. Consequences of sentinel node in clinical decision making in breast cancer and prospect for future studies
28. Sentinel node biopsy in breast cancer
29. Sentinel-lymph node biopsy for breast cancer - Not yet the standard of care
30. Lymphatic mapping and sentinel node biopsy in breast cancer
31. The challenge of sentinel lymph node biopsy
32. Sentinel node biopsy for breast cancer may have little to offer four-node samplers: Results of a prospective comparison study
33. Estimating the overlap between sentinel lymph node and axillary node sample in breast cancer
34. Prognostic importance of occult axillary lymph node micrometastases from breast cancer
35. Occult axillary lymph node metastases in "node-negative" breast carcinoma
36. Occult axillary lymph node metastases in invasive breast carcinoma: Characteristics of the primary tumor and significance of the metastases
37. Detection and significance of occult metastases in node-negative breast cancer
38. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
39. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction
40. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction
41. Pathologic correlates of prognosis in lymph node positive breast carcinomas
42. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast
43. Significance of axillary macrometastases and micrometastases in mammary cancer
44. Axillary micro- and macrometastases in breast cancer
45. Prognostic significance of breast cancer axillary lymph node micrometastasis assessed by two special techniques: Re-evaluation with longer follow-up
46. Importance of tumor cells in axillary sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma
47. Breast cancer: Two micrometastatic variants in the axilla that differ in prognosis
48. Prognostic significance of number and level of axillary node metastases in breast cancer
49. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work-up
50. Occult metastases in breast cancer are more likely to be detected in sentinel lymph nodes than in non-sentinel lymph nodes
51. Predicting treatment responsiveness and prognosis in node-negative breast cancer
52. Management and survival of female patients with 'minimal' breast cancer: As observed in the long-term and short-term surveys of the American College of Surgeons
53. Factors influencing survival and prognosis in early breast carcinoma (TINOMO-TINIMO). Assessment of 644 patients with median follow up of 19 years
54. Summary report of the Working Group to review the National Cancer Institute-American Cancer Society Breast Cancer Demonstration Detection Projects
55. Comparative study of the histopathology of breast cancer in a screened an unscreened population investigated by mammography
56. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening
57. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm
58. Minimal breast cancer: An update
59. Ueber assymetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung
60. Tubular carcinoma of the breast. A long-term follow-up
61. Pure mucinous carcinomas of the breast: Morphologic features and prognostic correlates
62. Invasive cribriform carcinoma of the breast
63. Medullary carcinoma of the breast - A clinicopathologic study with a ten year follow-up
64. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast
65. Tubulolobular invasive breast cancer: A variant of lobular invasive cancer
66. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma
67. Pathology of familial breast cancer: Differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases
68. Hereditary breast cancer. Pathobiology, prognosis and CRCA1 and BRCA2 gene linkage
69. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
70. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359. have been followed for 15 years
71. The position of histology in the prognosis of carcinoma of the breast
72. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
73. Recommendations for the reporting of breast carcinoma
74. Histologic grading of breast carcinoma: A reproducibility study
75. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histological grading scheme for infiltrating ductal carcinoma
76. Histological grading of breast carcinomas. A study of interobserver agreement
77. Pathological prognostic factors in stage I (TINOMO) and stage II (TINIMO) breast carcinoma: A study of 644 patients with median follow-up of 18 years
78. Prognostic significance of peritumoral vascular invasion in breast cancer
79. Topographic criteria in the diagnosis of tumor emboli in intramammary lymphatics
80. Pathological prognostic factors in breast cancer. III. Vascular invasion: Relationship with recurrence and survival in a large series with long-term follow-up
81. Tumor emboli in intramammary lymphatics in breast carcinoma: Pathological criteria for diagnosis and clinical significance
82. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary node metastases
83. Pathologic predictors of recurrence in stage I (TINOMO and T2NOMO) breast cancer
84. Pathologic findings from the National Surgical Adjuvant Projects for breast cancers (protocol no 4). IV. Significance of tumour necrosis
85. Relationship of necrosis and tumour border to lymph node metastases and 10 year survival in carcinoma of the breast
86. Morphometric analysis of breast carcinoma: Association with survival
87. A morphometric analysis of human breast carcinoma
88. Life expectancy following radical amputation for carcinoma of the breast - A clinical and pathological study of 218 cases
89. Tumour cellularity, oestrogen receptors and prognosis in breast cancer
90. Elastosis in benign and malignant breast disease
91. Steroid receptors in breast cancer
92. Is combined progesterone and oestrogen receptor (PR and ER) status better than ER alone in predicting hormone sensitivity in breast cancer?
93. A prognostic index in primary breast cancer
94. Type I Growth Factor Receptors. Current status and future work
95. 20 year update of the Naples Gun Trial of adjuvant breast cancer therapy: Evidence of interaction between C-erb-2 expression and tamoxifen efficacy
96. Prognostic and predictive relevance of C-erb-2 and ras expression in node positive and negative breast cancer
97. Expression of epidermal growth factor receptor and c-erb-2 during the development of tamoxifen resistance in human breast cancer
98. Elevated serum c-erb-2 antigen levels and decreased response to hormone therapy of breast cancer
99. Prediction of response to antioestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the Her-2/c-neu protein
100. Erb-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor negative breast cancer
101. Initial report of the SWOG biological correlative study of c-erb-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone
102. Overexpression of c-erb-2/neu in breast cancer cells confers increased resistance to taxol via mdr-I independent mechanisms
103. Her-2/neu (HER 2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer
104. Her-2/neu over-expression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer (MBC)
105. Phase II study of weekly intravenous recombinant humanized anti-p185 monoclonal antibody in patients with Her 2/neu overexpressing metastatic breast cancer
106. Confirmation of a prognostic index in primary breast cancer
107. A prognostic score in histological node negative breast cancer
108. Confirmation of a long-term prognostic index in breast cancer
109. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG)
110. Prognostic factors. ABC of Breast Diseases
111. Ten year results in a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
112. The prediction of local or regional recurrence after simple mastectomy for operable breast cancer
113. An audit of local recurrence after simple mastectomy
114. Post mastectomy radiotherapy in patients at high risk of loco-regional recurrence: A randomised trial
115. Risk of endometrial cancer after tamoxifen treatment of breast cancer
116. Efficacy and safety of Herceptin as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
117. Addition of Herceptin to firstline chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomised multinational controlled phase III trial
118. The importance of histological grade in invasive breast carcinoma and response to chemotherapy